Worldwide Incidence and Mortality of Biliary Tract Cancer

被引:28
作者
Baria, Katherine [1 ]
De Toni, Enrico N.
Yu, Binbing
Jiang, Zhuoxin
Kabadi, Shaum M.
Malvezzi, Matteo
机构
[1] Global Med Affairs AstraZeneca Pharmaceut, One MedImmune Way, Gaithersburg, MD 20878 USA
来源
GASTRO HEP ADVANCES | 2022年 / 1卷 / 04期
关键词
Biliary Tract Neoplasms; Epidemiological Studies; Patient-Focused Care; Public Health; CURRENT KNOWLEDGE; RISK-FACTORS; CHOLANGIOCARCINOMA; GALLBLADDER; EPIDEMIOLOGY; MULTICENTER; OBESITY; BURDEN; TRENDS;
D O I
10.1016/j.gastha.2022.04.007
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND AND AIMS: Biliary tract cancer (BTC) consists of a group of hepatic and perihepatic tumors that are in close proximity but are anatomically different, including gallbladder cancer (GBC), cholangiocarcinoma (extrahepatic and intrahepatic [ICC]), and ampulla of Vater cancer (AVC). Most epidemiologic research has focused on 1 or more anatomic subtypes, or does not differentiate BTC from hepatocellular carcinoma or other primary liver cancers. Here, we provide a descriptive update on global incidence and mortality rates for BTC, overall and by anatomic subtypes. METHODS: Age-standardized rates (per 100,000 person-years) were derived from the International Agency for Research on Cancer, Cancer Incidence in Five Continents, Volume XI (2008-2012; 22 countries), and the World Health Organization Mortality Database (2006-2016; 38 countries). RESULTS: BTC incidence varied by country, with the highest in Chile (14.35) and the lowest in Vietnam (1.25). Mortality rates for BTC were highest for the Republic of Korea (11.64) and lowest for the Republic of Moldova (1.65). BTC mortality rates increased over time in 24 of 34 countries. Patients aged >= 75 years had 5-10 times higher mortality rates than the overall BTC rate in all countries. In most countries, incidence rates were highest for GBC, and mortality rates highest for ICC, while both were lowest for AVC. Females had and died from GBC more frequently than males. For ICC, extrahepatic cholangiocarcinoma, and AVC, males trended toward higher incidence and mortality rates. CONCLUSION: The increasing incidence and mortality trends reported here indicate a need for improved prevention and treatment for all BTC subtypes.
引用
收藏
页码:618 / 626
页数:9
相关论文
共 42 条
[1]   Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [J].
Abou-Alfa, Ghassan K. ;
Macarulla, Teresa ;
Javle, Milind M. ;
Kelley, Robin K. ;
Lubner, Sam J. ;
Adeva, Jorge ;
Cleary, James M. ;
Catenacci, Daniel V. ;
Borad, Mitesh J. ;
Bridgewater, John ;
Harris, William P. ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Whisenant, Jonathan ;
Lowery, Maeve A. ;
Goyal, Lipika ;
Shroff, Rachna T. ;
El-Khoueiry, Anthony B. ;
Fan, Bin ;
Wu, Bin ;
Chamberlain, Christina X. ;
Jiang, Liewen ;
Gliser, Camelia ;
Pandya, Shuchi S. ;
Valle, Juan W. ;
Zhu, Andrew X. .
LANCET ONCOLOGY, 2020, 21 (06) :796-807
[2]   Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].
Abou-Alfa, Ghassan K. ;
Sahai, Vaibhav ;
Hollebecque, Antoine ;
Vaccaro, Gina ;
Melisi, Davide ;
Al-Rajabi, Raed ;
Paulson, Andrew S. ;
Borad, Mitesh J. ;
Gallinson, David ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Dotan, Efrat ;
Catenacci, Daniel, V ;
Van Cutsem, Eric ;
Ji, Tao ;
Lihou, Christine F. ;
Zhen, Huiling ;
Feliz, Luis ;
Vogel, Arndt .
LANCET ONCOLOGY, 2020, 21 (05) :671-684
[3]  
[Anonymous], 2018, National Program of Cancer Registries (NPCR)
[4]   Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) [J].
Banales, Jesus M. ;
Cardinale, Vincenzo ;
Carpino, Guido ;
Marzioni, Marco ;
Andersen, JesperB. ;
Invernizzi, Pietro ;
Lind, Guro E. ;
Folseraas, Trine ;
Forbes, Stuart J. ;
Fouassier, Laura ;
Geier, Andreas ;
Calvisi, Diego F. ;
Mertens, Joachim C. ;
Trauner, Michael ;
Benedetti, Antonio ;
Maroni, Luca ;
Vaquero, Javier ;
Macias, Rocio I. R. ;
Raggi, Chiara ;
Perugorria, Maria J. ;
Gaudio, Eugenio ;
Boberg, Kirsten M. ;
Marin, Jose J. G. ;
Alvaro, Domenico .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2016, 13 (05) :261-280
[5]   Hepatobiliary Cancers, Version 2.2021 [J].
Benson III, Al B. ;
D'Angelica, Michael I. ;
Abbott, Daniel E. ;
Anaya, Daniel A. ;
Anders, Robert ;
Are, Chandrakanth ;
Bachini, Melinda ;
Borad, Mitesh ;
Brown, Daniel ;
Burgoyne, Adam ;
Chahal, Prabhleen ;
Chang, Daniel T. ;
Cloyd, Jordan ;
Covey, Anne M. ;
Glazer, Evan S. ;
Goyal, Lipika ;
Hawkins, William G. ;
Iyer, Renuka ;
Jacob, Rojymon ;
Kelley, R. Kate ;
Kim, Robin ;
Levine, Matthew ;
Palta, Manisha ;
Park, James O. ;
Raman, Steven ;
Reddy, Sanjay ;
Sahai, Vaibhav ;
Schefter, Tracey ;
Singh, Gagandeep ;
Stein, Stacey ;
Vauthey, Jean-Nicolas ;
Venook, Alan P. ;
Yopp, Adam ;
McMillian, Nicole R. ;
Hochstetler, Cindy ;
Darlow, Susan D. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (05) :541-565
[6]   Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma [J].
Bertuccio, Paola ;
Malvezzi, Matteo ;
Carioli, Greta ;
Hashim, Dana ;
Boffetta, Paolo ;
El-Serag, Hashem B. ;
La Vecchia, Carlo ;
Negri, Eva .
JOURNAL OF HEPATOLOGY, 2019, 71 (01) :104-114
[7]  
Bray F, 2017, CI5 XI: cancer incidence in five continents, VXI
[8]   Epidemiology of gallbladder cancer in India [J].
Dutta, Usha ;
Bush, Nikhil ;
Kalsi, Dimple ;
Popli, Priyanka ;
Kapoor, Vinay K. .
CHINESE CLINICAL ONCOLOGY, 2019, 8 (04)
[9]   Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer [J].
Forte, Victoria ;
Pandey, Abhishek ;
Abdelmessih, Rita ;
Forte, Giovanna ;
Whaley-Connell, Adam ;
Sowers, James R. ;
McFarlane, Samy I. .
CARDIORENAL MEDICINE, 2012, 2 (02) :143-162
[10]   Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study [J].
Hong, Chai Yeong ;
Sinn, Dong Hyun ;
Kang, Danbee ;
Paik, Seung Woon ;
Guallar, Eliseo ;
Cho, Juhee ;
Gwak, Geum-Youn .
JOURNAL OF VIRAL HEPATITIS, 2020, 27 (09) :896-903